Martin J Duvall Net Worth

The estimated Net Worth of Martin J Duvall is at least $950 millier dollars as of 28 May 2019. Martin Duvall owns over 5,000 units of Tocagen stock worth over $949,629 and over the last 8 years Martin sold TOCA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Martin Duvall TOCA stock SEC Form 4 insiders trading

Martin has made over 1 trades of the Tocagen stock since 2019, according to the Form 4 filled with the SEC. Most recently Martin bought 5,000 units of TOCA stock worth $21,700 on 28 May 2019.

The largest trade Martin's ever made was buying 5,000 units of Tocagen stock on 28 May 2019 worth over $21,700. On average, Martin trades about 625 units every 0 days since 2017. As of 28 May 2019 Martin still owns at least 13,605 units of Tocagen stock.

You can see the complete history of Martin Duvall stock trades at the bottom of the page.

What's Martin Duvall's mailing address?

Martin's mailing address filed with the SEC is 3030 Bunker Hill St #230, San Diego, CA 92109, USA.

Insiders trading at Tocagen

Over the last 8 years, insiders at Tocagen have traded over $0 worth of Tocagen stock and bought 339,950 units worth $1,867,749 . The most active insiders traders include Faheem Hasnain, Steven Michael Oliveira et Franklin M Berger. On average, Tocagen executives and independent directors trade stock every 99 days with the average trade being worth of $2,157,169. The most recent stock trade was executed by Steven Michael Oliveira on 14 April 2020, trading 74,301 units of TOCA stock currently worth $88,418.

What does Tocagen do?

Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.

Complete history of Martin Duvall stock trades at Tocagen

Tocagen executives and stock owners

Tocagen executives and other stock owners filed with the SEC include:

• Fairooz Kabbinavar,
  Senior Vice President, Clinical Development
• Thomas Darcy,
  Director
• Peter Rahmer,
  IR Contact Officer
• Donald Williams,
  Director
• Patricia Walker,
  Director
• Steven Kornfeld,
  Director
• Lawrence Eichenfield,
  Director
• Antony Riley,
  Chief Financial Officer
• Paul Wagner,
  Chairman of the Board, President, Chief Executive Officer
• Steven Michael Oliveira,
  10% owner
• Asha Das,
  SVP & Chief Medical Officer
• Franklin M Berger,
  Director
• Paul Schimmel,
  Director
• Dennis N Berman,
  
• Harry E Gruber,
  President, Science&Innovation
• Douglas Jolly,
  EVP, Research & Pharm Devel
• Martin J Duvall,
  Chief Executive Officer
• Faheem Hasnain,
  Director
• Mark G Foletta,
  EVP & Chief Financial Officer
• David Ross Parkinson,
  Director
• Lori Anne Kunkel,
  Director